Comprehensive M&A data with integrated detailed company information

Nordic Capital to purchase OberScharrer
Posted on Tuesday, 13 March 2018 13:28
Palamon Capital Partners is selling Ober Scharrer Gruppe (OberScharrer), which is Germany’s largest provider of treatments for major causes of blindness and visual impairment, to a Nordic Capital fund for an undisclosed sum.

The deal will be subject to the receipt of approvals from the relevant regulatory bodies and the vendor expects it to generate returns of 3.6x invested capital.

No further details were announced.

Palamon has invested over EUR 440.00 million in the healthcare sector, including in Ulm-based group purchasing organisation Prospitalia, Spanish elderly care provider SARquavitae, and {my}dentist, which is the biggest dental operator in Britain.

Since the vendor’s initial purchase of a majority stake back in 2011, OberScharrer has tripled in size, now delivering over 85,000 treatments annually and holding a 5.0 per cent share in the fragmented EUR 2.40 billion German ophthalmology market.

The Fürth-headquartered target provides a range of treatments, including cataract operations, intravitreal operative drug application for degenerative eye disorders, and non-invasive procedures, as well as the diagnosis of eye disorders.

It was founded in 1892 and now has 900 employees treating over 500,000 patients each year from its 80 clinics located across Baden-Wurttemberg, Bavaria, and North Rhine-Westphalia.

Swedish private equity firm Nordic Capital has 28 companies in its current portfolio and, since it was established in 1989, has invested in over 20 healthcare platforms in Europe and the US.

According to its website, the company has completed 15.0 per cent of all the buyouts in the Nordic region over the last five years.

Joakim Lundvall, partner at the advisor to the Nordic Capital Funds, said the acquiror will now invest in and support OberScharrer’s “further development and growth in its field of expertise where we see a strong demand for specialised, high quality centres to provide treatment”.

© Zephus Ltd